Bright Minds Biosciences Inc. (DRUG) NASDAQ

72.50

-1.56(-2.11%)

Updated at December 04 04:00PM

Currency In USD

Bright Minds Biosciences Inc.

Address

1500 – 1055 West Georgia Street

New York City, BC V6E 4N7

Canada

Phone

647 407 2515

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

First IPO Date

March 22, 2021

Key Executives

NameTitlePayYear Born
Mr. Ian McDonaldCo-Founder, Chief Executive Officer, President & Director01988
Mr. Ryan E. S. K. Cheung B.Com., C.A., CPAChief Financial Officer85,1291978
Dr. Jan Torleif Pedersen M.Sc., Ph.D.Chief Science Officer & Director172,5991965
Mr. Alex VasilkevichChief Operating Officer & Senior Scientific Officer0N/A
Dr. Stephen D. Collins M.D., Ph.D.Chief Medical Officer01953
Dr. Emer Leahy M.B.A., Ph.D.Consultant01967

Description

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.